Why the study?
Does captopril prevent genetic hypertension development in young spontaneously hypertensive rats?
Does captopril prevent genetic hypertension development in young spontaneously hypertensive rats?
Early administration of captopril in spontaneously hypertensive rats prevents the development of genetic hypertension, with effects persisting long after treatment discontinuation.
Hypothesis-generating in genetic hypertension models; leaves open clinical translation to human prevention.
Captopril (100mg/kg) administered daily by gavage to young spontaneously hypertensive rats (SHRs) from their 6th to 20th weeks of age almost completely inhibited genetic hypertension development (GHD). This effect was correlated with an early and long-lasting limitation of the progressive increase in peripheral resistance which normally develops in SHRs during their growth. Heart rate, cardiac and systolic indexes remained unchanged, plasma renin concentration was significantly increased and heart weight/body weight ratio was significantly decreased. At last, captopril's GHD preventive effect persisted up to 12 weeks after treatment discontinuation.
No takes yet. Share an insight, caveat, or question.
Giudicelli et al. (1980) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: